PHOSPHODIESTERASE 10

Abstract: The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE10, and more particularly, binding partners that modulate PDE10 enzyme activity.

Description: PHOSPHODIESTERASE 10 This application claims priority of U.S. Provisional Application No. 60/075,508, filed February 23, 1998. FIELD OF THE INVENTION The present invention relates generally to a novel phosphodiesterase (PDE) designated PDEIO. Depending on nomenclature used, PDEIO is also referred to as PDE9. BACKGROUND OF THE INVENTION Phosphodiesterases (PDEs) hydrolyze 3', 5' cyclic nucleotides to their respective nucleoside 5' monophosphates. The cyclic nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl cyclases, respectively, and serve as second messengers in a number of cellular signaling pathways. The duration and strength of the second messenger signal is a function of the rate of synthesis and the rate of hydrolysis of the cyclic nucleotide. Multiple families of PDEs have been identified. The nomenclature system includes first a number that indicates the PDE family. To date, nine families (PDE 1-9) are known which are classified by: (i) primary structure; (ii) substrate preference; (iii) response to different modulators; (iv) sensitivity to specific inhibitors; and (v) modes of regulation [Loughney and Ferguson, in Phosphodiesterase Inhibitors. Schudt, et al. (Eds.), Academic Press: New York, New York (1996) pp. 1-19]. The number indicating the family is followed by a capital letter, indicating a distinct gene, and the capital letter followed by a second number, indicating a specific splice variant or a specific transcript that utilizes a unique transcription initiation site. The amino acid sequences of all mammalian PDEs identified to date include a highly conserved region of approximately 270 amino acids located in the carboxy terminal half of the protein [Charbonneau, et al, Proc. Natl. Acad. Sci. (USA) 53:9308-9312 (1986)]. The conserved domain includes the catalytic site for cAMP and/or cGMP hydrolysis and two putative zinc binding sites as well as family specific determinants [Beavo, Physiol Rev. 75:725-748 (1995); Francis, et al, J. Biol. Chem. 2(59:22477-22480 (1994)]. The amino terminal regions of the various PDEs are highly variable and include other family specific determinants such as: (i) calmodulin binding sites (PDE1); (ϋ) non-catalytic cyclic GMP binding sites (PDE2, PDE5, PDE6); (iii) membrane targeting sites (PDE4); (iv) hydrophobic membrane association sites (PDE3); and (v) phosphorylation sites for either the calmodulin-dependent kinase II (PDE1), the cAMP-dependent kinase (PDE1, PDE3, PDE4), or the cGMP dependent kinase (PDE5) [Beavo, Physiol Rev. 75:725-748 (1995); Manganiello, et al, Arch. Biochem. Ada 322: 1-13 (1995); Conti, et a , Physiol Rev. 75:723-748 (1995)]. Members of the PDE1 family are activated by calcium-calmodulin. Three genes have been identified; PDE1A and PDE IB preferentially hydro lyze cGMP while PDE1C has been shown to exhibit a high affinity for both cAMP and cGMP. The PDE2 family is characterized as being specifically stimulated by cGMP [Loughney and Ferguson, supra]. Only one gene has been identified, PDE2A, the enzyme product of which is specifically inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Enzymes in the PDE3 family are specifically inhibited by cGMP. Two genes are known, PDE3A and PDE3B, both having high aflBnity for both cAMP and cGMP, although the V max for cGMP hydrolysis is low enough that cGMP functions as a competitive inhibitor for cAMP hydrolysis. PDE3 enzymes are specifically inhibited by milrinone and enoximone [Loughney and Ferguson, supra]. The PDE4 family effects cAMP hydrolysis and includes four genes, PDE4A, PDE4B, PDE4C, and PDE4D, each having multiple splice variants. Members of this family are specifically inhibited by the anti-depressant drug rolipram. Members of PDE5 family bind cGMP at non-catalytic sites and preferentially hydrolyze cGMP. Only one gene, PDE5A, has been identified. The photoreceptor PDE6 enzymes specifically hydrolyze cGMP [Loughney and Ferguson, supra]. Genes include PDE6A and PDE6B (the protein products of which dimerize and bind two copies of a smaller γ inhibitory subunit to form rod PDE), in addition to PDE6C which associates with three smaller proteins to form cone PDE. The PDE7 family effects cAMP hydrolysis but, in contrast to the PDE4 family, is not inhibited by rolipram [Loughney and Ferguson, supra]. Only one gene, PDE7A, has been identified. The PDE8 family has been shown to hydrolyze both cAMP and cGMP and is insensitive to inhibitors specific for PDEs 1-5. Depending on nomenclature used, PDE8 is also referred to as PDEIO, but is distinct from PDE10 described herein. The PDE9 family preferentially hydrolyzes cAMP and is not sensitive to inhibition by rolipram, a PDE4-specific inhibitor, or isobutyl methyl xanthine (JDBMX), a non-specific PDE inhibitor. Depending on nomenclature used, PDE9 is also referred to as PDE8, but is distinct from PDE8 mentioned above. To date, two genes have been identified in the PDE9 family. Specific and non-specific inhibitors of the various PDE protein families have been shown to be effective in treating disorders attributable, in part, to aberrant levels of cAMP or cGMP. For example, the PDE4-specific inhibitor rolipram, mentioned above as an anti-depressant, inhibits lipopolysaccharide-induced expression of TNF and has been effective in treating multiple sclerosis in an animal model. Other PDE4-specific inhibitors are being investigated for use as anti-inflammatory therapeutics, and efficacy in attenuating the late asthmatic response to allergen challenge has been demonstrated [Harbinson, et al, Eur. Respir. J. 70:1008-1014 (1997)]. Inhibitors specific for the PDE3 family have been approved for treatment of congestive heart failure. PDE5 inhibitors are currently being evaluated for treatment of penile erectile dysfunction [Boolell, et al, Int. J. Impotence Res. S:47-50 (1996)]. Non-specific inhibitors, such as theophylline and pentoxifylline, are currently used in the treatment of respiratory and vascular disorders, respectively. Given the importance of cAMP and cGMP in intracellular second messenger signaling, there thus exists an ongoing need in the art to identify additional PDE species. Identification of heretofore unknown families of PDEs, and genes and splice variants thereof, will provide additional pharmacological approaches to treating conditions in which cyclic nucleotide pathways are aberrant, as well as conditions in which modulation of intracellular cAMP and/or cGMP levels in certain cell types is desirable. Identification of family-specific and enzyme-specific inhibitors will permit development of therapeutic and prophylactic agents which act on desired cell types expressing PDEs and/or particular metabolic pathways regulated by cyclic nucleotide monophosphate steady-state concentrations. SUMMARY OF THE INVENTION In brief, the prevent invention provides purified and isolated PDE10 polypeptides. Preferred polypeptides comprise the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22. The invention also provides polynucleotides encoding polypeptides of the invention. A preferred polynucleotide comprises the sequence set forth in SEQ ID NO: 1. Polynucleotides of the invention include polynucleotides encoding a human PDEIO polypeptide selected from the group consisting of: a) the polynucleotide according to SEQ ID NO: 1, 18, 20 or 22; b) a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code. Polynucleotides of the invention comprise any one of the polynucleotide set out in SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, as well as fragments thereof. The invention provide polynucleotides which are DNA molecules. DNA molecules include cDNA, genomic DNA, and wholly or partially chemically synthesized DNA molecule. The invention also provides antisense polynucleotides which specifically hybridizes with the complement of a polynucleotide of the invention. The invention also provides expression constructs comprising a polynucleotide of the invention, host cells transformed or transfected with an expression construct of the invention, and methods for producing a PDE 10 polypeptide comprising the steps of: a) growing the host cell of the invention under conditions appropriate for expression of the PDE10 polypeptide and b) isolating the PDE10 polypeptide from the host cell or the medium of its growth. The invention further provides antibodies specifically immunoreactive with a polypeptide of the invention. Preferably, the antibody is a monoclonal antibody. The invention also provides hybridomas which produces an antibody of the invention. Anti-idiotype antibody specifically immunoreactive with the antibody of the invention are also contemplated. The invention also provides methods to identify a specific binding partner compound of a PDE10 polypeptide comprising the steps of: a) contacting the PDE10 polypeptide with a compound under conditions which permit binding between the compound and the PDE10 polypeptide; b) detecting binding of the compound to the PDE10 polypeptide; and c) identifying the compound as a specific binding partner of the PDEIO polypeptide. Preferably, methods of the invention identify specific binding partners that modulate activity of the PDEIO polypeptide. In one aspect, the methods identify compounds that inhibits activity of the PDEIO polypeptide. In another aspect, the methods identify compounds that enhance activity of the PDEIO polypeptide. The invention also provides methods to identify a specific binding partner compound of the PDEIO polynucleotide of the invention comprising the steps of: a) contacting the PDEIO polynucleotide with a compound under conditions which permit binding between the compound and the PDEIO polynucleotide; b) detecting binding of the compound to the PDEIO polynucleotide; and c) identifying the compound as a specific binding partner of the PDEIO polynucleotide. Preferably, the methods identify specific binding partner compounds that modulate expression of a PDEIO polypeptide encoded by the PDEIO polynucleotide. In one aspect, method of the invention identify compounds that inhibit expression of the PDEIO polypeptide. In another aspect, methods of the invention identify compounds that enhance expression of the PDEIO polypeptide. Binding partner compounds identified by methods of the invention are also contemplated, as are compositions comprising the compound. The invention further comprehends use of binding partner compounds of the invention in production of medicaments for the treatment of PDElO-related disorders. DETAILED DESCRIPTION OF THE INVENTION The present invention provides polypeptides and underlying polynucleotides for a novel PDE family designated PDEIO. The PDEIO family is distinguished from previously known PDE families in that it shows a lower degree of sequence homology than would be expected for a member of a known family of PDEs and it is not sensitive to inhibitors that are known to be specific for previously identified PDE families. Outside of the catalytic region of the protein, PDEIO shows little homology to other known PDEs. Even over the catalytic region, PDEIO amino acid sequence identity is less than 40% when compared with the same region in known PDEs. The invention includes both naturally occurring and non-naturally occurring PDEIO polynucleotides and polypeptide products thereof. Naturally occurring PDEIO products include distinct gene and polypeptide species within the PDEIO family; these species include those which are expressed within cells of the same animal as well as corresponding species homologs expressed in cells of other animals. Within each PDEIO species, the invention further provides splice variants encoded by the same polynucleotide but which arise from distinct mRNA transcripts. Non-naturally occurring PDEIO products include variants of the naturally occurring products such as analogs (i.e., wherein one or more amino acids are added, substituted, or deleted) and those PDEIO products which include covalent modifications (i.e., fusion proteins, glycosylation variants, and the like). The present invention provides novel purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, including splice variants thereof) encoding human PDElOs. DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. Genomic DNA of the invention comprises the protein coding region for a polypeptide of the invention and includes allelic variants of the preferred polynucleotide of the invention. Genomic DNA of the invention is distinguishable from genomic DNAs encoding polypeptides other than PDE10 in that it includes the PDEIO coding region as defined by PDEIO cDNA of the invention. The invention therefore provides structural, physical, and functional characterization for genomic PDEIO DNA. Allelic variants are known in the art to be modified forms of a wild type gene sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are inherently naturally occurring sequences (as opposed to non-naturally occurring variants which arise from in vitro manipulation). "Synthesized," as used herein and is understood in the art, refers to purely chemical, as opposed to enzymatic, methods for producing polynucleotides. "Wholly" synthesized DNA sequences are therefore produced entirely by chemical means, and "partially" synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means. A preferred DNA sequence encoding a human PDEIO polypeptide is set out in SEQ ID NO: 1. The worker of skill in the art will readily appreciate that the preferred DNA of the invention comprises a double stranded molecule, for example the molecule having the sequence set forth in SEQ ID NO: 1 along with the complementary molecule (the "non-coding strand" or "complement") having a sequence deducible from the sequence of SEQ ID NO: 1 according to Watson-Crick base paring rules for DNA. Also preferred are polynucleotides encoding the PDEIO polypeptide of SEQ ED NO: 2. The disclosure of a full length polynucleotide encoding a PDEIO polypeptide makes readily available to the worker of ordinary skill in the art every possible fragment of the full length polynucleotide. The invention therefore provides fragments of PDElO-encoding polynucleotides of the invention comprising at least 10 to 20, and preferably at least 15, nucleotides, however, the invention comprehends fragments of various lengths. Preferably, fragment polynucleotides of the invention comprise sequences unique to the PDElO-encoding polynucleotide sequence, and therefore hybridize under stringent or preferably moderate conditions only (i.e., "specifically") to polynucleotides encoding PDEIO, or PDEIO polynucleotide fragments containing the unique sequence. Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs made available in public sequence databases. The invention also provides fragment polynucleotides that are conserved in one or more polynucleotides encoding members of the PDEIO family of polypeptides. Such fragments include sequences characteristic of the family of PDEIO polynucleotides, and are also referred to as "signature sequences." The conserved signature sequences are readily discernable following simple sequence comparison of polynucleotides encoding members of the PDEIO family. Fragments of the invention can be labeled in a manner that permits their detection, and radioactive and non-radioactive labeling are comprehended. Fragment polynucleotides are particularly useful as probes for detection of full length or other fragment PDEIO polynucleotides. One or more fragment polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding PDEIO, or used to detect variations in a polynucleotide sequence encoding PDE10. The invention further embraces species homologs, preferably mammalian, of the human PDEIO DNA. The polynucleotide sequence information provided by the invention makes possible the identification and isolation of polynucleotides encoding related mammalian PDEIO molecules by well known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to PDEIO and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of PDEIO. The invention also embraces DNA sequences encoding PDEIO species which hybridize under moderately stringent conditions to the non-coding strands, or complements, of the polynucleotide in any one of SEQ ID NOs: 1, 18, 20, and 22. DNA sequences encoding PDEIO polypeptides which would hybridize thereto but for the redundancy of the genetic code are contemplated by the invention. Exemplary moderate hybridization conditions are as follows: hybridization at 65°C in 3X SSC, 0.1% Sarkosyl, and 20 mM sodium phosphate, pH 6.8, and washing at 65 °C in 2X SSC with 0.1% SDS. Exemplary high stringency conditions would include a final wash in 0.2X SSC/0.1% SDS, at 65 °C to 75° C. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausebel, et al. (Eds.), Protocols in Molecular Biology. John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, etal, (Eds.), Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51. Autonomously replicating recombinant expression constructions such as plasmid and viral DNA vectors incorporating PDE10 sequences are also provided. Expression constructs wherein PDElO-encoding polynucleotides are operatively-linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator are also provided. According to another aspect of the invention, host cells are provided, including procaryotic and eucaryotic cells, either stably or transiently transformed with DNA sequences of the invention in a manner which permits expression of PDEIO polypeptides of the invention. Expression systems of the invention include bacterial, yeast, fungal, viral, invertebrate, and mammalian cells systems. Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with PDEIO. Host cells of the invention are also conspicuously useful in methods for large scale production of PDEIO polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown by, for example, immunoaffinity purification. Knowledge of PDEIO DNA sequences allows for modification of cells to permit, or increase, expression of endogenous PDEIO. Cells can be modified (e.g., by homologous recombination) to provide increased PDEIO expression by replacing, in whole or in part, the naturally occurring PDEIO promoter with all or part of a heterologous promoter so that the cells express PDEIO at higher levels. The heterologous promoter is inserted in such a manner that it is operatively-linked to PDEIO encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. The invention also comprehends that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the PDE10 coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the PDE10 coding sequences in the cells. The DNA sequence information provided by the present invention also makes possible the development through, e.g. homologous recombination or "knock-out" strategies [Capecchi, Science 2^: 1288-1292 (1989)], of animals that fail to express functional PDE10 or that express a variant of PDE10. Such animals are useful as models for studying the in vivo activities of PDE10 and modulators of PDE10. The invention also provides purified and isolated mammalian PDEIO polypeptides as set out in SEQ ID NOs: 2, 19, 21, and 23. Presently preferred is a PDEIO polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2. The invention embraces PDEIO polypeptides encoded by a DNA selected from the group consisting of: a) the DNA sequence set out in SEQ ID NOs: 1, 18, 20, or 22; b) a DNA molecule which hybridizes under stringent conditions to the noncoding strand of the protein coding portion of (a); and c) a DNA molecule that would hybridize to the DNA of (a) but for the degeneracy of the genetic code. The invention also embraces polypeptide fragments of the sequences set out in SEQ ID NOs: 2, 19, 21, or 23 wherein the fragments maintain biological or immunological properties of a PDEIO polypeptide. Preferred polypeptide fragments display antigenic properties unique to or specific for the PDEIO family of polypeptides. Fragments of the invention can be prepared by any the methods well known and routinely practiced in the art, having the desired biological and immunological properties. The invention embraces polypeptides have at least 99%,at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%), at least 55% and at least 50% identity and/or homology to the preferred PDE10 polypeptide on the invention. Percent amino acid sequence "identity" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the PDE10 sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence "homology" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the PDE10 sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity. Conservative substitutions can be defined as set out below. PDE10 polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of various host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. PDEIO products of the invention may be full length polypeptides, biologically or immunologically active fragments, or variants thereof which retain specific PDEIO biological or immunological activity. Variants may comprise PDEIO polypeptide analogs wherein one or more of the specified (i.e., naturally encoded) amino acids is deleted or replaced or wherein one or more non-specified amino acids are added: (1) without loss of one or more of the biological activities or immunological characteristics specific for PDEIO; or (2) with specific disablement of a particular biological activity of PDEIO. Variant products of the invention include mature PDEIO products, i.e., PDEIO products wherein leader or signal sequences are removed, and having additional, non-naturally occurring, amino terminal residues. PDEIO products having an additional methionine residue at position -1 (Met^-PDEIO) are contemplated, as are PDEIO products having additional methionine and lysine residues at positions -2 and -1 (Met^-Lys^-PDEIO). Variants of these types are particularly useful for recombinant protein production in bacterial cell types. The invention also embraces PDEIO variants having additional amino acid residues that result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide such as a glutathione-S-transferase (GST) fusion product provide the desired polypeptide having an additional glycine residue at position -1 as a result of cleavage of the GST component from the desired polypeptide. Variants which result from expression in other vector systems are also contemplated. Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Conservative substitutions are recognized in the art to classify amino acids according to their related physical properties and can be defined as set out in Table I (from WO 97/09433, page 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96). Table I Conservative Substitutions I SIDE CHAIN CHARACTERISTIC AMINO ACID Aliphatic Non-polar GAP ILV Polar - uncharged CSTM NQ Polar - charged DE KR Aromatic HFWY Other NQDE Alternatively, conservative amino acids can be grouped as defined in Lehninger, [Biochemistry. Second Edition; Worth Publishers, Inc. NY:NY (1975), pp.71-77] as set out in Table II. Table H Conservative Substitutions H SIDE CHAIN CHARACTERISTIC AMINO ACID Non-polar (hydrophobic) A. Aliphatic: ALIVP B. Aromatic: FW C. Sulfur-containing: M D. Borderline: G Uncharged-polar A. Hydroxyl: STY B. Amides: NQ C. Sulfhydryl: C D. Borderline: G Positively Charged (Basic): KRH Negatively Charged (Acidic): DE The invention further embraces PDEIO products modified to include one or more water soluble polymer attachments. Particularly preferred are PDEIO products covalently modified with polyethylene glycol (PEG) subunits. Water soluble polymers may be bonded at specific positions, for example at the amino terminus of the PDEIO products, or randomly attached to one or more side chains of the polypeptide. Also comprehended by the present invention are antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, human antibodies CDR-grafted antibodies, or otherwise "humanized" antibodies, antigen binding antibody domains including Fab, Fab', F(ab') 2 , F v , or single variable domains, and the like) and other binding proteins specific for PDEIO products or fragments thereof. Specific binding proteins can be developed using isolated or recombinant PDEIO products, PDEIO variants, or cells expressing such products. The term "specific for" indicates that the variable regions of the antibodies recognize and bind PDEIO polypeptides exclusively (i.e., able to distinguish PDEIO polypeptides from the superfamily of PDE polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al (eds), Antibodies: A Laboratory Manual: Cold Spring Harbor Laboratory; Cold Spring Harbor , NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the PDEIO polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, PDEIO polypeptides. As with antibodies that are specific for full length PDEIO polypeptides, antibodies of the invention that recognize PDEIO fragments are those which can distinguish PDEIO polypeptides from the superfamily of PDE polypeptides despite inherent sequence identity, homology, or similarity found in the family of proteins. Binding proteins are useful for purifying PDEIO products and detection or quantification of PDEIO products in fluid and tissue samples using known immunological procedures. Binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biological activities of PDEIO, especially those activities involved in signal transduction. Anti-idiotypic antibodies specific for anti-PDElO antibodies are also contemplated. The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA for PDE10 makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding PDEIO and PDEIO expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention under moderately to highly stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of PDEIO; allelic variants are known in the art to include structurally related proteins sharing one or more of the biochemical and/or immunological properties specific to PDEIO. Similarly, non-human species genes encoding proteins homologous to PDEIO can also be identified by Southern and/or PCR analysis and useful in animal models for PDElO-related disorders. As an alternative, complementation studies can be useful for identifying other human PDEIO products as well as non-human proteins, and DNAs encoding the proteins, sharing one or more biological properties of PDEIO. Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express PDEIO. Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in a PDEIO locus that underlies a disease state or states. The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of PDElOs. DNA and amino acid sequence information for PDEIO also permits identification of binding partner compounds with which a PDEIO polypeptide or polynucleotide will interact. Binding partner compounds include proteins and non-protein compounds such as small molecules. Agents that modulate (i.e., increase, decrease, or block) PDEIO activity or expression may be identified by incubating a putative modulator with a PDEIO polypeptide or polynucleotide and determining the effect of the putative modulator on PDEIO phosphodiesterase activity or expression. The selectivity of a compound that modulates the activity of the PDEIO can be evaluated by comparing its binding activity on the PDEIO to its activity on other PDE enzymes. Cell based methods, such as di-hybrid assays to identify DNAs encoding binding compounds and split hybrid assays to identify inhibitors of PDEIO polypeptide interaction with a known binding polypeptide, as well as in vitro methods, including assays wherein a PDEIO polypeptide, PDEIO polynucleotide, or a binding partner are immobilized, and solution assays are contemplated under the invention. Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to aPDElO polypeptide or a PDElO-encoding nucleic acid, oligonucleotides which specifically bind to a PDEIO polypeptide or a PDEIO gene sequence, and other non-peptide compounds (e.g., isolated or synthetic organic and inorganic molecules) which specifically react with a PDEIO polypeptide or underlying nucleic acid. Mutant PDEIO polypeptides which affect the enzymatic activity or cellular localization of the wild-type PDEIO polypeptides are also contemplated by the invention. Presently preferred targets for the development of selective modulators include, for example: (1) regions of the PDEIO polypeptide which contact other proteins and/or localize the PDEIO polypeptide within a cell, (2) regions of the PDEIO polypeptide which bind substrate, (3) cyclic nucleotide-binding site(s) of the PDEIO polypeptide, (4) phosphorylation site(s) of the PDEIO polypeptide and (5) regions of the PDEIO polypeptide which are involved in multimerization of PDEIO subunits. Still other selective modulators include those that recognize specific PDEIO encoding and regulatory polynucleotide sequences. Modulators of PDEIO activity may be therapeutically useful in treatment of a wide range of diseases and physiological conditions in which PDE activity is known to be involved. PDEIO polypeptides of the invention are particularly amenable to use in high throughput screening assays to identify binding partners, and preferably modulators. Cell based assays are contemplated, including yeast based assay systems as well as mammalian cell expression systems as described in Jayawickreme and Kost, Curr. Opin. Biotechnol. 5:629-634 (1997). Alternatively, automated and minaturized high throughput screening (HTS)assays, such as high density free format high density screening, as described in Houston and Banks, Curr. Opin. Biotehcnol 5:734-740 (1997). Combinatorial libraries are particularly useful in high throughput screening assays. There are a number of different libraries used for the identification of small molecule modulators, including, (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of structural analogs of known compounds or compounds that are identified as "hits" or "leads" via natural product screening. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) variants thereof. For a review, see Science 252:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opion. Biotechnol. 5:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to modulate activity. Also made available by the invention are anti-sense polynucleotides which recognize and hybridize to polynucleotides encoding PDEIO. Full length and fragment anti-sense polynucleotides are provided. The worker of ordinary skill will appreciate that fragment anti-sense molecules of the invention include (i) those which specifically recognize and hybridize to PDEIO RNA (as determined by sequence comparison of DNA encoding PDEIO to DNA encoding other known molecules) as well as (ii) those which recognize and hybridize to RNA encoding variants in the PDEIO family of proteins. Antisense polynucleotides that hybridize to RNA encoding other members of the PDEIO family of proteins are also identifiable through sequence comparison to identify characteristic, or signature, sequences for the family of molecules. Anti-sense polynucleotides are particularly relevant to regulating expression of PDEIO by those cells expressing PDEIO mRNA. Antisense nucleic acids (preferably 10 to 20 base pair oligonucleotides) capable of specifically binding to PDEIO expression control sequences or PDEIO RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the PDEIO target nucleotide sequence in the cell and prevents transcription or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use according to the invention. The antisense oligonucleotides may be further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at the 5' end. The invention further comprehends methods to modulate PDEIO expression through use of ribozymes. For a review, see Gibson and Shillitoe, Mol Biotech. 7:125-137 (1997). Ribozyme technology can be utilized to inhibit translation of PDEIO mRNA in a sequence specific manner through (i) the hybridization of a complementary RNA to a target mRNA and (ii) cleavage of the hybridized mRNA through nuclease activity inherent to the complementary strand. Ribozymes can identified by empirical methods but more preferably are specifically designed based on accessible sites on the target mRNA [Bramlage, et al, Trends in Biotech 7(5:434-438 (1998).] Delivery of ribozymes to target cells can be accomplished using either exogenous or endogenous delivery techniques well known and routinely practiced in the art. Exogenous delivery methods can include use of targeting liposomes or direct local injection. Endogenous methods include use of viral vectors and non-viral plasmids. Ribozymes can specifically modulate expression of PDEIO when designed to be complementary to regions unique to a polynucleotide encoding PDEIO. "Specifically modulate" therefore is intended to mean that ribozymes of the invention recognizes only a polynucleotide encoding PDEIO. Similarly, ribozymes can be designed to modulate expression of all or some of the PDEIO family of proteins. Ribozymes of this type are designed to recognize polynucleotide sequences conserved in all or some of the polynucleotides which encode the family of proteins. The invention further embraces methods to modulate transcription of PDE10 through use of oligonucleotide-directed triplet helix formation. For a review, see Lavrovsky, et al, Biochem. Mol. Med. (52: 11-22 (1997). Triplet helix formation is accomplished using sequence specific oligonucleotides which hybridize to double stranded DNA in the major groove as defined in the Watson-Crick model. Hybridization of a sequence specific oligonucleotide can thereafter modulate activity of DNA-binding proteins, including, for example, transcription factors and polymerases. Preferred target sequences for hybridization include promoter and enhancer regions to permit transcriptional regulation of PDEIO expression. Oligonucleotides which are capable of triplet helix formation are also useful for site-specific covalent modification of target DNA sequences. Oligonucleotides useful for covalent modification are coupled to various DNA damaging agents as described in Lavrovsky, et al. [supra]. The invention comprehends mutations in the PDEIO gene that result in loss of normal function of the PDEIO gene product and underlie human disease states in which failure of the PDEIO is involved. Gene therapy to restore PDEIO activity would thus be indicated in treating those disease states. Delivery of a functional PDEIO gene to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275- 1281 (1989); Verma, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455- 460 (1992). Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of PDE10 will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of PDE10. Identification of modulators of PDE10 expression and/or biological activity provides methods to treat disease states that arise from aberrant PDE10 activity. Modulators may be prepared in compositions for administration, and preferably include one or more pharmaceutically acceptable carriers, such as pharmaceutically acceptable (i.e., sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma. The modulator compositions can be packaged in forms convenient for delivery. The compositions can be enclosed within a capsule, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the composition into the recipient organism and, particularly, when the composition is being delivered in unit dose form. The dosage units can be packaged, e.g., in tablets, capsules, suppositories or cachets. The compositions may be introduced into the subject by any conventional method including, e.g., by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, or subcutaneous injection; by oral, sublingual, nasal, anal, vaginal, or transdermal delivery; or by surgical implantation, e.g., embedded under the splenic capsule or in the cornea. The treatment may consist of a single dose or a plurality of doses over a period of time. The invention also embraces use of a PDEIO polypeptide, a PDEIO polynucleotide, or a binding partner thereof in production of a medicament for treatment of a PDElO-related biological disorder. The present invention is illustrated by the following examples relating to the isolation of a polynucleotide encoding a PDEIO polypeptide and expression thereof. Example 1 describes identification of an EST encoding a partial PDEIO polypeptide and isolation of a full length PDElO-encoding clone. Example 2 relates to Northern blot analysis of PDEIO expression. Example 3 addresses chromosome mapping of PDEIO. Example 4 describes expression and characterization of a recombinant PDEIO polypeptide. Example 5 describes production of anti-PDElO antibodies. Example 6 provides an analysis of PDEIO expression using in situ hybridization. Example 7 relates to high throughput screening to identify inhibitors of PDEIO. Example 1 Identification of an EST Related to a Human PDE and Isolation of a Full Length PDElO-encoding Polynucleotide Using the sequences of known human, 3 ', 5' cyclic nucleotide phosphodiesterases, a search of the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database was undertaken in order to identify cDNA fragments that could potentially be useful for the identification of novel phosphodiesterase (PDE) genes. This database contains DNA sequences representing one or both ends of cDNAs collected from a variety of tissue sources. A single sequencing run is performed on one or both ends of the cDNA and the quality of the DNA sequence varies tremendously. At the time the PDE searches were performed, the EST sequence database contained more than 600,000 cDNA sequences from a variety of organisms. The search for novel PDE sequences included three steps. First, the BLASTN program available through NCBI was used to identify DNA sequences in the EST sequence database with homology to cDNA sequences encoding known human PDEs. The program compares a nucleotide query sequence against a nucleotide sequence database. The cDNA sequences of the fifteen known human PDEs were submitted and fifteen BLASTN searches were performed; the query PDE sequences included PDE 1 A3 [Loughney, et al, J. Biol. Chem. 277:796-806 (1996)], PDE1B1 [Yu, et al, Cell Signaling, 9:519-529 (1997)], PDE1C2 [Loughney, et al, J. Biol. Chem. 277:796-806 (1996)], PDE2A3 [Rosman, et al, Gene 797:89-95 (1997)], PDE3A [Meacci, et al, Proc. Natl. Acad. Sci. (USA) 59:3721-3725 (1992)], PDE3B [Miki et al, Genomics 3(5:476-485 (1996)], PDE4A5 [Bolger,et al, Mol Cell. Biol. 73:6558-6571 (1993)], PDE4B2 [Bolger, etal, Mol. Cell. Biol. 73:6558-6571 (1993)], PDE4C [Bolger, et al, Mol. Cell. Biol. 73:6558-6571 (1993)], PDE4D1 [Bolger, et al, Biochem. J. 325:539- 548 (1997)] and PDE4D3 [Bolger, et al, Mol. Cell. Biol 73:6558-6571 (1993)], PDE5A, PDE6A [Pittier, et al, Genomics 6:272-283 (1990)], PDE6B [Collins, et al, Genomics 73:698-704 (1992)], PDE6C [Piriev, et al, Genomics 25:429-435 (1995), and PDE7A1 [Michaeli, etal, J. Biol. Chem. 77:12925-12932 (1993)]. The BLASTN results were examined and EST sequences that were judged as corresponding to each of the fifteen known PDE cDNAs were identified and collected into a table. The PDE6A and PDE6B sequences used as queries were truncated at 3 ' end (removing a portion of the 3 ' untranslated region) due to the presence of repetitive elements in the 3 ' untranslated region of the cDNAs. Secondly, the NCBI TBLASTN program was used to examine the homology between the protein sequence of the fifteen known human PDEs (as above) and the six different possible proteins encoded by each of the EST DNA sequences. In this search, the EST sequences are translated in the six possible reading frames and the amino acid sequences generated are compared to the query PDE amino acid sequences. Sequences identified as homologous at the amino acid level were examined and any EST sequences positively identified as corresponding to a known PDE during the BLASTN search described above were discarded. The third step of the search involved analyzing the sequences that were not known PDEs. These amino acid sequences were homologous to a known PDE but were not identified as one of the 15 known PDE genes during the BLASTN searches. The initial BLAST searches identified three EST sequences, designated X88347 (SEQ ID NO: 3), X88467 (SEQ ID NO: 4), and X88465 (SEQ ID NO: 5), that were obtained from an exon trapping experiment using chromosome 21 genomic DNA and found to encode an amino acid sequence having homology to the catalytic region of one or more of the PDE query sequences. X88347 showed homology with the amino acid sequences of PDE1A, IB, 1C, 3 A, 3B, 4A, 4B and 4D; X88467 showed homology to PDE1A, IB, 1C, 4A, 4B, 4C, and D4; and X88465 was homologous to PDE1 A and IB amino acid sequences. At the 5' terminus, EST X88465 was 58 nucleotides shorter than was X88467 and was not considered further. When X88347 was translated from nucleotides 1-222 and the resultant protein was compared to PDE1 A, the two proteins were the same at 23 of 51 amino acid positions (45% identity). When X88467 was translated from nucleotide 3 to 155 and the resultant protein compared to PDE1A, 15 of 36 amino acids were the same (42% identity). Because ESTs X88347 and X88467 showed homology to two different regions of the catalytic region of PDE1 A, it seemed possible that they represented two different exons from a novel PDE gene. X88347 was used as a query in a BLASTN search of the NCBI EST database. In addition to itself, X88347 identified three other human EST sequences with high enough homology to suggest the sequences were derived from the same gene. EST R00718 (SEQ ID NO: 6) showed 91% identity to X88347. R00719 (SEQ ID NO: 7) represented the 3 '-end of the same cDNA as R00718. R45187 (SEQ ID NO: 8) showed 88% identity to X88347. Two mouse cDNAs were also identified; W82786 (SEQ ID NO: 9)(91% identity) and W 10517 (SEQ ID NO: 10) appeared to represent the mouse homolog of X88347. A BLASTN search using W10517 as probe identified another sequence H90802 (SEQ ID NO: 11), which appeared to represent another human EST that may be part of the human PDE gene. The several human cDNAs were not identical to each other, and the quality of the sequencing was poor. The cDNA represented by the R00719 and R00718 EST sequences was obtained from the American Type Culture Collection (Rockville, MD) which maintains and makes publicly available deposits of ESTs identified and sequenced by I.M.A.G.E., Lawrence Livermore National Laboratory, (Livermore, CA). The cDNA had been isolated from a fetal liver and spleen library and mapped to chromosome 21. R00718/9 was sequenced upon receipt and found to be consistent with the EST database sequence. The polynucleotide and amino acids sequences for R00718/9 are set out in SEQ ID Nos: 12 and 13, respectively. The R00718/9 clone contained a 0.6 kb insert with a poly A tail at the 3 '-end. The open reading frame encoded a protein with homology to other PDEs but did not extend to the 5 'end of the cDNA. Beginning at amino acid position 9, a QSDRE sequence was found. Corresponding D and E residues were found within all of the query sequences. Query sequences also included a conserved E(F/Y) sequence located amino terminal to the conserved D and E residues, but this sequence was not found in EST R00718/9. Instead, the EST contained eight amino acids followed by a stop codon. The R00718/9 cDNA appeared to diverge from the PDE query sequences in the catalytic region and the open reading frame was not maintained. The disrupted open reading frame may suggest the presence of an intron that had not been removed or that the R00718/9 sequence was joined to some unidentified extraneous polynucleotide sequence. The gene represented by R00718/9 was designated PDEIO. In order to identify additional PDEIO sequences, a probe was generated based on the PDEIO sequence and used to screen cDNA libraries. First, two primers, R71S100R (SEQ ID NO: 14) and R71A521H (SEQ ID NO: 15) were synthesized for use in PCR to amplify a 420 nucleotide portion of the R00718/9 DNA fragment (nucleotides 130 to 550). Primer R71S100R generated anEcoRI restriction site in the amplification product (underlined below) and primer R71A521H generated a Hindϊϊl site (also underlined below). The PCR fragment was designed to include the region of R00718/9 homologous to other PDEs, but not the poly A tail. R71S100R (SEQ ID NO: 14) AGTCGAATTCACCGTGAGAAGTCAGAAG R71A521H (SEQ ID NO: 15) GTCAAAGCTTACATGGTCTTGTGGTGCC The PCR reaction contained 50 pg R00719 cDNA, 10 ng/μl each primer, 0.2 mM dNTP, IX PCR buffer (Perkin-Elmer), 2 mM MgCl 2 , and 1.25 U Taq polymerase (Perkin-Elmer). The reaction was first maintained at 94 °C for four minutes, after which thirty cycles of one minute 94°C, two minutes 50°C, and four minutes at 72°C were performed. The PCR fragment was purified using low melting point agarose gel electrophoresis. For library screening, the PCR fragment was labeled with 32 P with a random priming kit (Boehringer Mannheim) according to manufacturer's instructions and used to screen 10 6 cDNAs from a human heart cDNA library (Stratagene, La Jolla, CA), 5 x 10 5 cDNAs from a human hippocampal cDNA library (Clontech, Palo Alto, CA), and 7.5 x 10 5 cDNAs from a human fetal brain cDNA library (Stratagene). Hybridization was carried out overnight in buffer containing 3X SSC, 0.1% Sarkosyl, 20 mM sodium phosphate, pH 6.8, 10X Denhardt's solution, and 50 μg/ml salmon sperm DNA at 65 °C Eleven positives were obtained from the fetal brain library and three from the hippocampal library. Partial sequencing led to the selection of one, FB79c, for further characterization. The polynucleotide and deduced amino acid sequences for FB79c are set out in SEQ ID NOs: 16 and 17, respectively. FB79c contained a 1.3 kb insert; the 3 'end of FB79c extended further than that of R00718/9 and contained 12 adenosine residues of the poly A tail of R00718/9, an Ec RI site (GGAATTC), an additional fifty-nine nucleotides and a poly A sequence. At the 5 'end, the sequence for FB79c differed from that of R00718/9 beginning at, and continuing 5 ' of, nucleotide 121 of R00718/9 (corresponding to nucleotide 744 of FB79c). The open reading frame in FB79c (encoding a protein with homology to the query PDEs) did not extend to the 5 'end of the cDNA but ended in a stop codon at nucleotide 104. A sequence within the FB79c DNA located upstream of the point of divergence from R00718/9 (but within the portion of the open reading frame with homology to the other PDEs ) was the region chosen for a probe in subsequent library screening. The isolated sequence selected was a 0.36 kb EcoRV fragment extending from nucleotide 308 to nucleotide 671 of FB79c and was used to screen 1.75 x 10 6 cDNAs from the fetal brain cDNA library (Stratagene). More than twenty cDNAs were identified and twelve were subjected to partial restriction mapping and DNA sequencing. More extensive sequencing on six of them led to the selection of clones FB76.2 and FB68.2 for complete sequencing. The polynucleotide and amino acid sequences for clone FB76.2 are set out in SEQ ID NOs: 18 and 19, respectively, and the polynucleotide and amino acid sequences for clone FB68.2 are set out in SEQ ID NOs. 20 and 21, respectively. FB76.2 contained a 1.9 kb cDNA insert; the 3 'end of the cDNA stopped one nucleotide short of the poly A tail found in clone FB79c and the sequence diverged from FB79c 5' of nucleotide 109 in clone FB79c (corresponding to nucleotide 715 in FB76.2). The open reading frame in the FB76.2 sequence that encoded a protein with homology to the PDE query sequences extended to the 5 'end of the cDNA and the first methionine was encoded beginning at nucleotide 74. Assuming this residue to be the initiating methionine, the open reading frame of FB76.2 encoded a 533 amino acid protein with a predicted molecular weight of 61,708 Da. Clone FB68.2 contained a 2 kb cDNA insert. At the 3 'end, it extended to the poly A tail found in the FB79c sequence and the open reading frame extended to the 5 'end of the cDNA. FB68.2 differed from FB76.2 by the presence of an additional internal 180 nucleotides (nucleotides 225 to 404 of FB68.2) following corresponding nucleotide 335 of FB76.2. Since the number of additional nucleotides in the FB68.2 insertion was divisible by three, it did not alter the reading frame as compared to FB76.2. The position of the insert with respect to maintaining the same reading frame suggested that the sequence might represent an exon found in some, but not all, PDE10 cDNAs. Alternatively, the additional sequence could be an intron that had not been removed from the FB68.2 cDNA. Because the FB76.2 and FB68.2 differed from each other, additional PDE10 DNAs were obtained and analyzed to more accurately define the PDE10 nucleotide sequence. A 5' 0.3 kb Eco l fragment of FB76.2 (corresponding to nucleotides 1 to 285) was isolated and used as a probe to screen 7.5 x 10 5 cDNAs from the fetal brain cDNA library. Thirty seven positives were obtained, of which nineteen were first characterized with respect to fragment size (insert) that hybridized to the 0.3 kb EcoRI probe. Eight of the nineteen clones were subsequently characterized by partial sequencing. Two clones, FB93a and FB94a, contained 0.5 kb and 1.6 kb EcoRI fragments, respectively, that hybridized and were chosen for complete sequencing. The polynucleotide and amino acid sequences for clone FB93a are set out in SΕQ ID NOs: 22 and 23, respectively, and the polynucleotide and amino acid sequences for clone FB94a are set out in SΕQ ID NOs : 1 and 2, respectively. FB93a contained a 1.5 kb insert which did not extend to the 3 'end of FB76.2 but was ninety nucleotides longer than FB76.2 at the 5 'end. The additional nucleotides encoded a stop codon beginning at position 47 which was in reading frame with the first methionine in FB76.2 described above (nucleotide 164 in FB93a). The position of the stop codon indicated the presence of a complete open reading frame and that FB76.2 probably represented a full length cDNA. Like FB76.2, FB93a did not contain the 180 nucleotide insert that was present in FB68.2. FB94a contained a 1.5 kb cDNA insert and the 3 'end extended almost 0.1 kb beyond the stop codon. The first methionine was encoded beginning at nucleotide 26, and assuming this residue to be the initiating methionine, FB94a encoded a 466 amino acid protein with a predicted molecular weight of 54,367 Da. FB94a differed from FB76.2 and FB93a by absence of a 149 nucleotide region which, if consistent with the sequences for FB76.2 and FB93a, would have been located after nucleotide 42. The absence of the 149 nucleotide sequence produced a putative initiator methionine that is in a different reading frame than that found in FB76.2 and FB93a. Like FB76.2 and FB93a, FB94a did not contain the 180 nucleotide region found in FB68.2. A search of the ΕST data base with the FB94a and FB93a sequences identified yet another possible sequence for a PDΕ10 cDNA. The sequence of ΕST A158300 lacked both the 149 nucleotide and the 180 nucleotide sequences discussed above. In addition, A158300 also lacked 55 nucleotides immediately 3 ' to the 180 nucleotide region as found in the FB68.2 sequence. The open reading frame in A158300 extended to the 5 'end and the first methionine corresponded to the same one used by FB76.2 and FB93a. The presence of the additional 55 nucleotide deletion from A158300 resulted in a different reading frame for the sequence between the site where the 149 nucleotides were deleted and the site where the 180 nucleotides were deleted. The sequence information for PDEIO derived from these cDNA sequences can be summarized as follows. There is a 149 nucleotide sequence found in some clones (sequences FB76.2, FB93a, FB68.2) but not in all (sequences FB94a, A158300). The 149 nucleotide sequence is followed by a 44 nucleotide region that is present in all the PDEIO cDNAs analyzed to date. Following the 44 nucleotide region is a sequence of 235 nucleotides in length. The region can be present in its entirety (as found in the sequence for FB68.2) or without the first 180 nucleotides (as observed in sequences FB76.2 and FB93a). As still another alternative, the whole region can be removed (as found in the sequence for Al 58300). These possibilities predict six different mRNA structures, four of which have been isolated. The presence or absence of the 149 nucleotide region may reflect the presence or absence of an exon, and the presence of all or some of the 235 nucleotide region may reflect alternative 3 'splice acceptor site usage. As an alternative, it is also possible that the 235 nucleotide region represents two separate exons of 180 and 55 nucleotides in length. The presence or absence of the 149 nucleotide sequence alters the reading frame of the encoded protein as does the presence or absence of the 55 nucleotide sequence. A number of single nucleotide differences have been observed in comparison of the various PDE10 cDNAs. R00718/9 has a cytosine at nucleotide position 155 whereas the other cDNAs have a thymidine at this position; this difference represented a silent change as proline is encoded by both sequences. R00718/9 also has a cytosine at position 161 whereas the other cDNAs have an adenosine at the same position; this difference also represented a silent change as both sequences encode alanine. FB94a has a guanosine at position 1383 whereas the other cDNAs have an adenosine at this position; as a consequence of the difference, FB94a encodes a glycine rather than a glutamic acid at that position. FB76.2 has an adenosine rather than a cytosine at position 1809; the difference does not effect an amino acid difference since the nucleotide position is located in the 3 ' untranslated region. FB79c also has one less adenosine in the string of nucleotides between 1204 and 1215 than do the other cDNAs; this difference is also within the 3 ' untranslated region. In comparison of a predicted PDEIO amino acid sequence with other known PDEs indicated that most, but not all, of the amino acids that are conserved among the query sequences were also found in PDEIO. Comparison of the PDEIO catalytic region to PDE4A, PDE5A, and PDE7A revealed 32%, 30% and 34% identity, respectively. Example 2 Northern Blot In order to determine which cell and tissue types express PDEIO, Northern blot analysis was carried out using a commercially prepared multi-tissue Northern blot (Clontech, Palo Alto, CA). The probe was a EcoKl/Bcll fragment of the FB76.2 corresponding to nucleotides 1 to 883. Hybridization conditions were as previously described [Loughney et al., supra, (1996)]. Results indicated a 2.2 to 2.4 kb band which was strongest in kidney, present in heart, pancreas, and placenta, and weakest in brain, lung, skeletal muscle and liver. The band was fairly wide in placenta suggesting that it might contain a number of mRNAs of slightly different sizes. Example 3 Chromosome Mapping As mentioned above, the X88347, X88467, and X88465 ESTs were identified with an exon trapping procedure using DNA from chromosome 21 [Chen et al 1996]. X88467 was identified as a new sequence with homology to a mouse calcium-, calmodulin-dependent phosphodiesterase Q01065 aa 52-103. XD88347 was identified to be the same as EST R00718 and similar to Drosophila cAMP dependent phosphodiesterase PI 2252. Both of these sequences were placed in a category described as having strong homology to known protein sequences. A search of the Sequence Tagged Sites (STS) database at NCBI revealed homology of the 3 '-end of PDE10 to STS WI-13322 which has been mapped to region 220.72 cr. from the top of chromosome 21. The cDNA that this STS was derived from begins at nucleotide 1899 of FB68.2, does not have the poly A tail and extends further 3 ' than FB68.2. It seems likely that this STS sequence represents a PDEIOA transcript to which no poly (A + ) tail has been added or a PDEIOA transcript that uses an alternative site for poly (A + ) addition. STS WI-13322 was placed on a Whitehead map of chromosome 21 near SGC35805, which is derived from the gene for the cystathionine beta-synthase (CBS). CBS has been mapped to chromosome 21 at 21q22.3 [Avramopoulos, et al, Hum. Genet. 90:566-568 (1993); Munke et al, Hum. Genet. 42:550-559 (1988)]. A number of different genetic diseases map to this region of chromosome 21, for example, Down syndrome [Delabar, etal, Eur. J. Hum. Genet.1: 114-124(1993)]. It is not clear that PDEIOA falls within the Down syndrome critical region (DSCR) but it is possible that genes elsewhere on chromosome 21 also contribute to Down syndrome [Korenberg, et al, Proc. Natl. Acad. Sci. (USA) 97:4997-5001 (1994)]. As another example, a locus involved in bipolar affective disorder in some families has been mapped to 21q22.3 [Vallada, etal, J.Affect. Disord. ¥7:217-221 (1996)]. Other examples include Knobloch syndrome, characterized by myopia and retinal degeneration and detachment [Sertie, etal, Hum. Mol. Genet. 5:843-847 (1996)], and one or more genes responsible for congenital recessive deafness (DFNB8, DFNB10) [Veske, et al, Hum. Mol Genet. 5: 165168 (1996); Bonne-Tamir, et al, Am. J. Hum. Genet. 58: 1254-1259 (1996)]. PDEIOA may play a role in any or all of these disease states. Example 4 Expression and Characterization of PDE10 The entire open reading frame of the PDE10 cDNA (clone FB94a) was placed into a yeast ADH vector including the alcohol dehydrogenase promoter. The construct was built in two steps. The 5 'end was generated using PCR and FB94a DNA as template. PCR was carried out using the 5 ' primer below (SEQ ID NO: 25) in combination with 3 ' primer R71A3 (SEQ ID NO: 26) . The 5' primer includes an Ncol site (underlined in SEQ ID NO: 25 below) and the initiating methionine codon of FB94a is in bold. The 5' primer ® also adds a FLAG epitope tag (Eastman Kodak, Rochester, NY) to the amino terminus ® of the encoded protein; the FLAG tag is an epitope (SEQ ID NO: 24) recognized by the monoclonal antibody M2 (Eastman Kodak). FLAG ® TAG (SEQ ID NO: 24) Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys 5' Primer (SEQ ID NO: 25) TAGACCATGGACTACAAGGACGACGA- TGACAAGATGGACGCATTCAGAAGCACT R71A3 (SEQ ID NO: 26) CGAGGAGTCAACTTCTTG PCR was carried out using 5 μl each primer (100 μg/ l stock), 5 μl 10X buffer (Perkin Elmer), 5 μl 10X nucleotides (2 mM stock), 3 μl MgCl 2 (25 mM stock), FB94a DNA, and 0.3 μl Taq polymerase (Perkin Elmer) in a reaction volume of 50 μl. After incubating the reaction mixture at 94 °C for four minutes, 30 cycles of one minute at 94 °C, two minutes at 50°C, and four minutes at 72°C were carried out. The PCR product was cleaved with Ncol and Hindi and purified using agarose gel electrophoresis. The 3 'sequence of PDE10 was isolated as a Hincll/EcoRI fragment cleaved from FB94a and purified by agarose gel electrophoresis. The two fragments were combined and ligated into a ® NcoI/EcoRI-digested Bluescript vector (Stratagene, La Jolla, CA), previously modified by the insertion of the ADH promoter previously removed from a YΕpC-PADH2d vector [Price et al Meth. Enzymol 755:308-315 (1990)] as a Sacl/Ncol fragment, to generate plasmid PDElO-1. New junctions and sequence generated by PCR were verified by sequencing. In the second step of plasmid construction, the Sacl/Sa l fragment from PDE10-1 containing the ADH promoter and PDE10 open reading frame was purified by two rounds of agarose gel electrophoresis and ligated into Sacl/Sall cut YEpC-PADH2 vector. Following transformation into BJ2-54, a yeast strain lacking endogenous PDE activity, a colony was selected, streaked out on SC-leu plates and a single colony carrying the PDE10 construct was chosen for further characterization. Following overnight growth in SC-leu media the culture was diluted 1 :250 in fresh SC-leu and grown overnight at 30°C until it reached a density of 10 7 cells/ml. The cells were collected by centrifugation, washed once with YEP 3% glycerol media, resuspended in YEP containing 3% glycerol, and grown at 30° C for another 24 hours. The cells were harvested by centrifugation, washed with water, and frozen at -70 °C until use. Prior to use, an aliquot of the yeast extract was analyzed by SDS PAGE. A protein specific to yeast carrying the PDEIO expression construct that migrated on the SDS PAGE gels with the expected mobility (55.5 kDa) was observed by Coomassie blue staining. Yeast cells ( 1 x 10 10 ) were thawed with 200 μg/ml each of pepstatin A, leupeptin, and aprotinin 1 mM DTT, and 20 μg/ml calpain inhibitors (I and II). Two hundred μl of glass beads (0.5 mm, acid washed) were added, and the mixture was vortexed for eight cycles of 30 seconds each. Samples were cooled for 4.5 minutes at 4°C between cycles. After lysis, 0.8 ml lysis buffer was added, the lysate separated from the beads, and the lysate centrifuged for 30 minutes at 100,000 x g in a Beckman TL-100 tabletop centrifuge. The supernatant was aliquoted, frozen in dry ice/ethanol, and stored at -70°C. ® Kinetic assays were performed on a BIOMEK 1000 programmable robotic station (Beckman Instruments). The range of final substrate concentration was 0.2 to 1000 μM for cAMP and 0.6-2000 nM for cGMP. The highest nucleotide concentration contained 1 to 1.5 million Cerenkov counts of 32 P-labeled substrate per assay. The enzyme preparation was initially diluted 1:500 (cAMP as substrate) or 1:50,000 (cGMP as substrate). The enzyme dilution buffer consisted of 25 M Tris-HCl pH 8.9, 5 μM ZnSO 4 5 mM MgCl 2 , 0.1 mM DTT, 100 mM NaCl and 0.1 mg/ml BSA (Calbiochem; fatty acid free). Activity at each substrate concentration was derived from a linear fit of successive four-fold enzyme dilutions across the plate. Assays were performed at 30°C for 15 minutes. After 12 minutes, 5 μl snake venom from Crotalus atrox (15 mg/ml protein) was added to each reaction. Assays were stopped by addition 200 μl of charcoal suspension (25 mg/ml activated charcoal in 0.1 M monobasic potassium phosphate). The plate was centrifuged at 2600 rpm, and 200 ® μl of each supernatant was transferred into Microbeta counting plates and counted on ® a WALLAC Microbeta by Cerenkov counting. Data were evaluated with a predesigned ® Microsoft Excel Spreadsheet, and the kinetic parameters were fitted to a Michaelis- ® Menton model using the program Table Curve from Jandel Scientific. Results indicated that the K,,, for cGMP hydrolysis was 5 (± 1) nM and the K.-- for cAMP hydrolysis was 160 (± 30) μM. In the extract, cGMP hydrolytic activity was determined to be 0.035 (± 0.01) μmol/min/mg, while cAMP hydrolysis was measured to be 0.52 (± 0.06) μmol/min/mg. Thus, although PDE10 had much greater affinity for cGMP, the V max for cAMP was 15-fold greater. In order to distinguish PDE10 from other PDE families, a panel of PDE inhibitors with activities against defined PDE families was tested for PDE10 inhibition using cAMP as a substrate. The results of the assay are set out in Table 1 below. TABLE 1 PDE10 Inhibition with Isozyme-specific PDE Inhibitors Inhibitor Target PDE10 Target Family Family IC 50 ( μM) IC 50 (μM) SCH46642 PDE1 14 0.2 5 EHNA PDE2 477 0.8 2 Cilostamide PDE3 100 0.04-0.9 3 Rolipram PDE4 529 0.18-0.5 4 DMPPO PDE5 9 0.003 * IBMX non-specific 59 2-20 1 1. Coste and Grodin, Biochem. Pharmacol 50: 1577-1585 (1995). 2. Podzuweit, et al. Cell Signaling 7:733-738 (1995) 3. Manganiello et al, in Isoenzymes of Cyclic Nucleotide Phosphodiesterases. Beavo and Houslay (Eds.), John Wiley and Sons, Ltd. , pp. 87-116 (1990) 4. Bolger et al, Mol. Cell. Biol. 73:6558-6571 (1993) 5. Ahn, et al, Abstract from the 9th International Conference on Second Messengers and Phosphoproteins, Nashville, TN, 1995, p. 86. The results further distinguish PDEIO from PDEs in families 1 through 5 in that specific inhibitors for enzymes in those families are significantly less effective in inhibiting PDEIO. Example 5 Production of Anti-PDEIO Antibodies A GST fusion protein was produced in E. coli to provide an antigen for generation of monoclonal antibodies to PDEIO. An EcoRI fragment from FB76.2 (nucleotides 280 through 1829 in SΕQ ID NO: 18) was inserted into the EcoRI site of pGΕX3X (Pharmacia) and the resultant construct was transformed in the E. coli strain XL1 Blue. A GST-PDE10 fusion protein including 464 amino acids from PDEIO was expressed from this construct following induction with IPTG. The fusion protein was isolated using SDS-PAGE, the band of appropriate size excised from the gel following staining with cold 0.4 M KC1, and the protein obtained from the acrylamide by electroelution. The elution product was dialyzed against PBS and concentrated using Centriprep 10 and Centricon columns (Amicon, Beverly MA) prior to being injected into mice. On day 0, four Balb/c mice were pre-bled and immunized by subcutaneous injection with a panel of antigens including 30 μg/mouse GST-PDE10 fusion protein in complete Freund's adjuvant in 200 μl total volume. The same injections were repeated at weeks three and nine in incomplete Freund's adjuvant. Ten days after the last immunization, test bleeds were obtained and screened by antigen capture ELISA and Western analysis. ® In the ELISA, Immulon 4 plates (Dynex, Cambridge, Massachusetts) were coated at 4°C with 50 μl/well of a solution containing 2 μg/ml GST-PDE10 in 50 mM carbonate buffer, pH 9.6. Plates were blocked with 0.5% fish skin gelatin (Sigma) for 30 minutes and 50 μl serum diluted in PBS with 0.5% Tween® 20 (PBST) was added. Serum dilutions ranged from 1:100 to 1: 102,400 and were obtained by a series of doubling dilutions. After incubation at 37°C for 30 minutes and washing three times with PBST, 50 μl of horseradish peroxidase-conjugated goat anti-mouse IgG(fc) antibody (Jackson) (diluted 1: 10000 in PBST) was added. Plates were incubated as above and washed four times with PBST. Antibody was detected with addition of tetramethyl benzidine (Sigma Chemical, St. Louis, Missouri) and the color reaction was stopped after five minutes with the addition of 50 μl of 15% H 2 SO 4 . Absorbance at 450 nM was measured on a plate reader. For Western analysis, SDS-PAGE gels were run with approximately 10 μg yeast PDEIO extract and approximately 200 ng of gel-purified GST-PDE10 and the proteins were transferred to Immobilon-PVDF. A standard enhanced chemiluminescence (ECL) Western blot protocol was performed using BioRad goat anti-mouse IgG horseradish peroxidase as the secondary antibody. In preparation of hybridomas, splenocytes from mice giving a positive result from the ELISA and/or Western blotting protocols above, were fused to NS- 1 cells in a ratio of 5: 1 by standard methods using polyethylene glycol 1500 (Boehringer Mannheim) [Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory, p.211 (1988)]. The fused cells were resuspended in 200 ml RPMI containing 15%) FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5 x 10 6 murine thymocytes/ml and dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 μl/well. Cells were fed on days 2, 4, and 6 post fusion by aspirating approximately 100 μl from each well with an 18 G needle (Becton Dickinson) and adding 100 μl/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes. On days 9 to 12, supernatants from the fusion wells were screened by antigen capture ELISA using GST and GST-PDE10 and by ECL Western analysis as described above. A positive signal of the expected size was obtained on both lanes of the Western blot using mouse blood and monoclonal antibodies with reactivity to the yeast recombinant protein were obtained in the subsequent fusion. Example 6 Analysis of PDE10 Expression by in situ Hybridization Expression of PDE10 was examined in tissue sections by in situ hybridization as described below. Preparation of probe An EcoKl/Pstl restriction enzyme fragment from the cDNA FB93a (corresponding to nucleotides 370 through 978 in SEQ ID NO: 22) was subcloned into ® a Bluescript vector (Stratagene, La Jolla, CA) to generate an expression plasmid designated PDE10A3 A. The plasmid was digested with EcoRI and transcribed with T3 polymerase to generate an antisense probe. A sense probe was generated by digestion the plasmid with BamHl and transcribing with T7 polymerase. The PDΕ10 templates were transcribed using a RNA Transcription kit (Stratagene, La Jolla, CA) in a reaction containing 5 μl of 5X transcription buffer (Stratagene), 30 mM DTT (Stratagene), 0.8 mM each ATP, CTP, GTP (10 mM (Stratagene), 40 U RNase Block II (Stratagene), 12.5 U T3 or T7 polymerase (Stratagene), and 300 ng linearized plasmid template, 50 μCi 35 S- UTP (greater than 1000 Ci/mmol, Amersham, Arlington Heights, IL). The mixture was incubated at 37° C for one hour after which the template DNA was removed by addition of 1 μl of RNase-free DNase I (Stratagene) and incubation for 15 minutes at 37 °C. The probe was hydrolyzed to approximately 250 nucleotides in length to facilitate tissue penetration by adding 4 μl 1 M NaHCO 3 and 6 μl 1 M for 22 minutes at 60 °C and the reaction mixture was neutralized by addition of 25 μl of a solution containing 100 μl 3 M sodium acetate, 5 μl acetic acid (VWR, So. Plainfield, NJ), and 395 μl dH 2 0. A Quick Spin G50 RNA column (5 '-3' Inc., Boulder, CO) was prepared according to the manufacturer's suggested protocol. The probe was placed in the center of the column and the column centrifuged for four minutes at 1,000 rpm in a desk top centrifuge. The column flow-through was mixed with 50 μl dH 2 O, 2 μl of a 10 mg/ml tRNA solution, 10 μl 3 M sodium acetate, and 200 μl 100%) ethanol (VWR) and the resulting mixture was incubated at -20 °C overnight. The probe solution was microfuged for 15 minutes at 4°C, the supernatant was removed, and the pellet was resuspended in 40 μl IX TBΕ containing 1 μl of 0.1 M DTT. The probe was stored at -70 °C until the in situ hybridization assay was performed. Preparation of tissue samples and in situ hybridization Tissues (National Disease Research Interchange, Philadelphia, PA and Cooperative Human Tissue Network, Philadelphia, PA) were sectioned at 6 μm and placed on Superfrost Plus slides (VWR). Sections were fixed for 20 minutes at 4°C in 4% paraformaldehyde (Sigma, St. Louis, MO). The slides were rinsed in three changes of IX calcium-, magnesium-free phosphate buffered saline (CMF-PBS), dehydrated with three successive washes with 70% ethanol, 95%> ethanol and 100%> ethanol , and dried for 30 minutes at room temperature. The slides were placed in 70% formamide (J.T. Baker) in 2X SSC for two minutes at 70°C, rinsed in 2X SSC at 4°C, dehydrated through 70%, 95%) and 100% ethanol washes, and dried for 30 minutes at room temperature. A prehybridization step was performed by placing the slides in an airtight box containing a piece of filter paper saturated with buffer containing 50% formamide (J.T. Baker) in 4X SSC. Each section was covered with 100 μl of rHB2 buffer consisting of 10% dextran sulfate (Sigma), 50% formamide (J.T. Baker, Phillpsburg, NJ), 100 M DTT (Boehringer Mannheim, Indianapolis, IN), 0.3 M NaCl (Sigma), 20 mM Tris, pH 7.5, 5 mM EDTA (Sigma), and IX Denhardt's solution (Sigma) and the slides were incubated at 42 °C for two hours. The probe, as described above, was prepared by mixing 4 x 10 5 cpm/tissue section with 5 μl of a 10 mg/ml tRNA solution per section and heating the mixture at 95 °C for three minutes. Ice cold rHB2 buffer was added to bring the final volume to 20 μl/section. The probe-containing solution (20 μl/section) was added to 100 μl rHB2 buffer previously applied. The slides were incubated at 55°C for 12 to 16 hours. Following hybridization, the slides were washed once in 4X SSC containing 10 mM DTT for one hour at room temperature, once in 50% deionized formamide (J.T. Baker), IX SSC, and 1 mM DTT for 40 minutes at 60°C, once in 2X SSC for 30 minutes at room temperature, and once in 0. IX SSC for 30 minutes at room temperature. The sections were dehydrated through 70%, 95%, and 100% ethanol washes and air dried for 30 minutes. The slides were dipped in Kodak NTB2 nuclear emulsion, dried for one to three hours at room temperature in the dark, and stored in the dark at 4°C with desiccant until ® time of development. The slides were developed in 4°C Kodak Dektol developer for two minutes, dipped four times in 4°C dH 2 O, and placed in 4°C Kodak fixer for ten minutes. The slides were rinsed in dH 2 O and a standard hematoxylin and eosin (H&E) stain was performed as follows. The slides were rinsed in dH 2 O and stained with hematoxylin and eosin by transfer of the slides through a series of the following steps: five minutes in formaldehyde/alcohol (100 ml formaldehyde, 900 ml 80% ethanol); three rinses in water for a total of two minutes; five minutes in 0.75% Harris hematoxylin (Sigma); three rinses in water for a total of two minutes; one dip in 1% HCl/50%> ethanol; one rinse in water; four dips in 1% lithium carbonate; ten minutes in tap water; two minutes in 0.5% eosin (Sigma); three rinses in water for a total of two minutes; two minutes in 70% ethanol; three one-minute rinses in 95% ethanol; two one-minute rinses in 100%) ethanol; and two two-minute rinses in xylene. Slides were mounted with cytoseal 60 (Stephens Scientific, Riverdale, NJ). The signals obtained with an antisense PDE10 probe were compared to the control signals generated by a sense PDE10 probe and any signal specific to the antisense probe was assumed to represent PDE10 expression. PDE10 signal was detected throughout much of the cerebellum, with very strong signal in the Purkinje cells. Example 7 High Throughput Screening for PDE10 Inhibitors In an attempt to identify specific inhibitors, PDE10 was screened against a chemical library containing compounds of known structure. Initial screening was performed on pools of compounds (22 compounds per pool) with each compound present at 4.6 μM. Pools which inhibited PDE10 activity by greater than 50%o were selected and the individual compounds in the pool were screened at a concentration of 20 μM. IC 50 values were determined for compounds that inhibited enzyme activity. An extract was prepared from Saccharomyces cerevisiae strain BJ2-54 (described in Example 4) lacking endogenous PDE activity and having PDE10 at an activity of 49 nmol cGMP hydrolyzed/min ml with 32 nM cGMP. The extract was diluted 1:21 ,000-fold for use in the assay. Dilution buffer included 25 mM Tris, pH 8.0, 0.1 mM DTT, 5.0 mM MgCl 2 , 100 mM NaCl, 5 μM ZnSO 4 and 100 μg/ml BSA. PDE assay buffer (5X) contained 200 mM Tris, pH 8.0, 5 mM EGTA, 25 mM MgCl 2 and 0.5 mg/ml BSA. Just prior to screening, 5X PDE assay buffer, deionized water, and 5 -nucleosidase (stock solution 15 mg/ml snake venom 5'-nucleosidase in 20 mM Tris, pH 8.0) were mixed at ratios of 4:4: 1 to make Assay Reagent Mix. ® A Packard MultiPROBE was used to add 45 μl of the Assay Reagent ® Mix and 20 μl of the chemical compound pools. A BIOMEK 1000 (See Example 4) was used to add 20 μl of PDEIO extract diluted as described above and 20 μl 32 P-cGMP (ICN, specific activity 250 μCi/mmol, diluted to 0.4 μCi ml, 16 nM, in deionized water). Final cGMP concentration in the assay was 0.08 μCi/ml, 3.2 nM. Ten minutes after addition of 32 P-cGMP, 140 μl of 25 mg/ml charcoal (in 0.1 M NaH 2 PO 4 ) was added to stop the reaction. After a 20 minute incubation at room temperature, the assay plates were centrifuged for five minutes at 3,500 rpm in a Beckman GS-6R centrifuge. A ® BIOMEK 1000 was used to transfer 140 μl of the supernatant to a Wallac counting plate and Cerenkov radiation was measured in a Wallac MicroBeta Counter. Several compounds that merit further investigation were found to inhibit enzyme activity. Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

Claims: What is claimed is: 1. A purified and isolated PDE10 polypeptide. 2 The polypeptide according to claim 1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22. 3. A polynucleotide encoding the polypeptide according to claim 1 or 2. 4. The polynucleotide according to claim 3 comprising the sequence set forth in SEQ ID NO: 1. 5. A polynucleotide encoding a human PDEIO polypeptide selected from the group consisting of: a) the polynucleotide according to claim 4; b) a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code. 6. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 18. 7. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 20. 8. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 22. 9. The polynucleotide of claim 5 which is a DNA molecule. 10. The DNA of claim 9 which is a cDNA molecule. 11. The DNA of claim 9 which is a wholly or partially chemically synthesized DNA molecule. 12. A polynucleotide comprising the sequence set out in SEQ ID NO: 1 or a fragment thereof. 13. A polynucleotide comprising the sequence set out in SEQ ID NO: 18 or a fragment thereof. 14. A polynucleotide comprising the sequence set out in SEQ ID NO: 20 or a fragment thereof. 15. A polynucleotide comprising the sequence set out in SEQ ID NO: 22 or a fragment thereof. 16. An anti-sense polynucleotide which specifically hybridizes with the complement of the polynucleotide of claim 5. 17. A expression construct comprising the polynucleotide according to claim 5. 18. A host cell transformed or transfected with the expression construct according to claim 17. 19. A method for producing a PDE10 polypeptide comprising the steps of: a) growing the host cell according to claim 18 under conditions appropriate for expression of the PDEIO polypeptide and b) isolating the PDEIO polypeptide from the host cell or the medium of its growth. 20. An antibody specifically immunoreactive with the polypeptide according to claim 1 or 2. 21. The antibody according to claim 20 which is a monoclonal antibody. 22. A hybridoma which produces the antibody according to claim 21. 23. An anti-idiotype antibody specifically immunoreactive with the antibody according to claim 21. 24. A method to identify a specific binding partner compound of the PDEIO polypeptide according to claim 1 or 2 comprising the steps of: a) contacting the PDEIO polypeptide with a compound under conditions which permit binding between the compound and the PDEIO polypeptide; b) detecting binding of the compound to the PDEIO polypeptide; and c) identifying the compound as a specific binding partner of the PDEIO polypeptide. 25. The method according to claim 24 wherein the specific binding partner modulates activity of the PDEIO polypeptide. 26. The method according to claim 25 wherein the compound inhibits activity of the PDEIO polypeptide. 27. The method according to claim 25 wherein the compound enhances activity of the PDEIO polypeptide. 28. A method to identify a specific binding partner compound of the PDEIO polynucleotide according to claim 5 comprising the steps of: a) contacting the PDEIO polynucleotide with a compound under conditions which permit binding between the compound and the PDEIO polynucleotide; b) detecting binding of the compound to the PDEIO polynucleotide; and c) identifying the compound as a specific binding partner of the PDEIO polynucleotide. 29. The method according to claim 28 wherein the specific binding partner modulates expression of a PDEIO polypeptide encoded by the PDEIO polynucleotide. 30. The method according to claim 29 wherein the compound inhibits expression of the PDEIO polypeptide. 31. The method according to claim 29 wherein the compound enhances expression of the PDEIO polypeptide. 32. A compound identified by the method according to claim 24 or 28. 33. A composition comprising the compound according to claim 32 and a pharmaceutically acceptable carrier.

Inventors: LOUGHNEY KATE, LOUGHNEY, KATE
Applicants: ICOS CORP, ICOS CORPORATION
Application year: 1999
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K45, A61P43, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12Q1, G01N33